News EC conditionally approves Pfizer’s haemophilia B gene therapy The approval is based on data from the Phase III BENEGENE-2 clinical trial of DURVEQTIX.
Features Flexibility of alternative trial designs crucial for cell and gene therapy research Abigail Beaney and Irena Maragkou